Jackie Walling 

Jackie Walling, MBChB, Ph.D., is a pharmaceutical executive with extensive experience in the global clinical development of anticancer drugs and drugs for rare genetic diseases. As an experienced CMO, she has worked on multiple complex drug development programs and has extensive experience with regulatory agencies. 

With over 30 years of experience, she has a proven history in global oncology drug development with both small molecules and biologics, and for hematologic malignancies and solid tumors across phases I -IV. She has contributed to numerous approvals including those for gemcitabine, pemetrexed, talazoparib, elosulfase, and more recently relugolix.

Prior to becoming a CMO, Dr. Walling held VP positions at BioMarin and at Axys Pharmaceuticals. Earlier she worked at Tularik after starting her pharmaceutical career at Eli Lilly. 

A British trained physician, Dr Walling received her MBChB from the University of Bristol. She received her PhD from the University of Southampton, UK working on the mechanism of action of 2 anticancer drugs. She also conducted postdoctoral research in oncology at the MRC Radiobiology Unit at Harwell, and at the University of Aston, Birmingham.